Home > Insider Trading > Filing (0001209191-21-012117)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1654151	Deciphera Pharmaceuticals Inc.	DCPH	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1410514	Patrick Thomas Kelly	C/O Deciphera Pharmaceuticals, Inc. 200 Smith Street Waltham MA 02451	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-02-16	524	$48.87	6,516	No	4	S	Direct
Common Stock	Acquisiton	2021-02-16	11,100	$0.00	17,616	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2021-02-16	49,900	$0.00	49,900	$47.79

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
49,900		2031-02-15	No	4	A	Direct

Footnotes

The sale was to cover tax liabilities in the vesting of restricted stock.
The reporting person was awarded 11,100 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2022, February 15, 2023, February 15, 2024 and February 15, 2025. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 16, 2021.